Apyx Medical Corporation reaffirmed earnings guidance for the full year ending December 31, 2024. Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December 31, 2023. Net loss attributable to stockholders of approximately $26.5 million to $24.3 million, compared to $18.7 million for the year ended December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +3.12% | +3.12% | -37.02% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.02% | 57.16M | |
-7.16% | 178B | |
-1.23% | 107B | |
-4.86% | 67.04B | |
-4.28% | 47.23B | |
+10.32% | 44.62B | |
+8.14% | 42.5B | |
+15.53% | 25.22B | |
-5.88% | 24.14B | |
-5.38% | 23.69B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024